LUPUS RESEARCH ALLIANCE INC

The lupus research alliance (lra) has made significant strides in advancing its scientific mission through strategic planning, program expansion and operational improvements.in 2024, the lra successfully developed and implemented the first-year goals of its 20242028 research strategy. In alignment with the updated research strategy, lra launched several innovative, patient-centric research initiatives, including the translational bridge award, the targeted research program on engineered cell therapies, the renewed cycle of the common mechanisms in autoimmune diseases program, and the mechanistic clinical studies award. Additionally, the organization began developing a lupus biomarkers strategy and initiated the development of a comprehensive data strategy, scheduled for completion in 2025.lra's current grant programs, including the global team science award (gtsa), career development award, post doctoral award, and lupus innovation award --were expanded and optimized through active staff oversight and strategic collaborations. This included launching a request for applications in a collaborative program across the gtsa and continuing the administrative supplement training program.to raise the visibility of its research programs, lra submitted multiple abstracts to international scientific meetings, several were accepted and will be presented in 2025. The organization also hosted a successful and engaging annual investigator's and program specific meetings: forum for discovery, alliance of gtsa and other program-specific research meetings in november of 2024. Operational improvements included the selection and implementation of a new grant management system, the recruitment and onboarding of two staff scientists and a lupus abc administrator, and the strengthening of the research team through targeted team-building and professional development efforts. Lupus abc has been successfully established as a model public-private partnership in the regulatory space, demonstrating leadership and innovation in advancing lupus research and experienced substantial growth in membership during 2024. The initiative secured active participation from the fda's center for biologics evaluation and research, reinforcing its credibility and collaborative strength. A major milestone was the fda's acknowledgment of clasi 70 as a primary efficacy endpoint in cutaneous lupus clinical trials, marking a significant advancement in clinical outcome measurement. Additionally, lupus abc convened a dedicated patient-reported outcomes (pro) meeting to further integrate patient perspectives into research and regulatory strategies. Lupus nexus completed its infrastructure build and officially launched to both research and patient communities. It finalized foundational analysis plans, selected key vendors, and recruited 200 participants. Additionally, 10 new clinical sites were activated through lucin (see below), and a sustainable financial model with a defined membership fee structure was established. Lupus therapeutics, llc :the lra founded lupus therapeutics, llc (lt) as the clinical research affiliate of the lra in 2018. With this addition, the lra is the only organization leading lupus research across the continuum from accelerating basic discoveries in the lab through clinical evaluation of new therapies. Many of the basic research breakthroughs supported by the lra have helped unravel the complexities of lupus and enabled the development of potential treatments and diagnostics now in clinical studies. Lt is actively supporting several clinical studies for new therapies through the lupus clinical investigators network (lucin). Lt oversees lucin, a north america-based lupus clinical trials network of 60+ premier research medical centers. The lra provided over $2.6 million in grants in 2024 to continue funding top academic centers to foster robust, high quality clinical trial conduct with participation across north america.lt also offers expertise combined with that of 250+ lucin providers and the lra to support academic, nonprofit and biotech and pharmaceutical organizations to plan, initiate and manage clinical research. This occurs through diverse advisory services and direct clinical operations support. An annual lucin community meeting is held to bring together all of the partners in clinical research to highlight recent advancements, bolster understanding, address current challenges in clinical research and encourage collaboration for successful development of new treatment approaches.in addition, lt has expanded the first peer-to-peer clinical trials education program, patient advocates for lupus studies or pals to include trial buddy support during participation in clinical trials. Pals aims to improve clinical research awareness, knowledge and enrollment, with a specific focus on making sure populations at greatest risk for lupus are well represented in studies. Lt also supports other patient engagement activities such as patient advisory boards, patient visits and patient protocol review committees to ensure that individuals impacted by lupus have a voice in the treatment development process. Finally, lt efforts support various education offerings for providers and patients, and community-based outreach to ensure representative participation of the entire lupus community in clinical research.